Are quality medicines affordable? Evidence from a large survey of medicine price and quality in Indonesia
Open Access
- 24 May 2025
- journal article
- Published by BMJ in BMJ Global Health
- Vol. 10 (5) , e015416
Abstract
Background: Since Indonesia implemented one of the world’s largest single-payer health insurance schemes in 2014, the price of many common medicines has fallen dramatically. Industry groups warn unsustainably low prices threaten quality, while the government says medicines remain overpriced. We investigate the relationship between the price and quality of essential medicines and the affordability of medicines paid for out of pocket.Methods: We bought over 1000 samples of five common prescription medicines—allopurinol, amlodipine, amoxicillin, cefixime and dexamethasone—online and from randomly selected pharmacies and health facilities in four regions across Indonesia. We recorded the price paid and tested samples for quality using high-performance liquid chromatography. We compared prices with the median and lowest prices for each medicine, tested for correlation between quality and price, and calculated affordability compared with the district minimum wage.Results: Medicines available in the public procurement system were less likely to fail quality testing than other brands/varieties (4.2% vs 8.3%) but the difference was not statistically significant (p=0.086). There was no other relationship between quality and price, or branded status. Branded generic medicines sold at a large variety of price points, from 0.3 to 18.6 times the median price for the medicine and dose (IQR: 0.9–5.0, median 1.4). Unbranded generics traded in a narrower range (range 0.1–2.6; IQR 0.6–1.0, median 0.8). Medicines were most expensive in the region with the lowest wages, but even there, medicines selling at the 25th percentile of available prices cost a maximum of 0.7% of 1 day’s wage for a course.Conclusion: In every study district, we found that Indonesian patients working at the minimum wage could access affordable, quality-assured versions of all studied essential medicines. More expensive brands were also widely available, but there was no relationship between price and quality.Keywords
All Related Versions
Funding Information
- NIHR Global Health Policy and Systems Research (NIHR131145)
This publication has 22 references indexed in Scilit:
- The Impact of Pharmaceutical Policies on Medicine Procurement Pricing in Indonesia Under the Implementation of Indonesia’s Social Health Insurance SystemValue in Health Regional Issues, 2020
- Strategies to achieve fairer prices for generic and biosimilar medicinesBMJ, 2020
- Insulin price components: case studies in six low/middle-income countriesBMJ Global Health, 2019
- Use of medicine pricing and reimbursement policies for universal health coverage in IndonesiaPLOS ONE, 2019
- “No generics, Doctor!” The perspective of general practitioners in two French regionsBMC Health Services Research, 2017
- Perceptions of generic medication in the general population, doctors and pharmacists: a systematic reviewBMJ Open, 2015
- What do people really think of generic medicines? A systematic review and critical appraisal of literature on stakeholder perceptions of generic drugsBMC Medicine, 2015
- A comparative evaluation of price and quality of some branded versus branded-generic medicines of the same manufacturer in IndiaIndian Journal of Pharmacology, 2011
- "This body does not want free medicines": South African consumer perceptions of drug qualityHealth Policy and Planning, 2009
- Pharmaceutical Policy In ChinaHealth Affairs, 2008